Acarbose and Secondary Prevention After Coronary Stenting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the intervention for newly diagnosed abnormal glucose tolerance after coronary stenting will improve the long-term clinical outcome.
| Condition | Intervention | Phase |
|---|---|---|
|
Glucose Metabolism Disorders Coronary Artery Disease |
Drug: Acarbose |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study) |
- Cardiovascular event free survival time
- Conversion of abnormal glucose tolerance to type 2 diabetes
- All causes of death
- Occurrence of every cardiovascular event
- Occurrence of in-stent restenosis
- Change in fasting, 2-hour blood glucose and insulin level
- Change in homeostasis model assessment of insulin resistance
- Change in hemoglobin A1c (HbA1c)
- Change in lipid profile
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2005 |
| Study Completion Date: | April 2009 |
Recent studies have demonstrated that newly diagnosed abnormal glucose tolerance (AGT; diabetes mellitus and impaired glucose tolerance) are common among the patients with ischemic heart disease. Several large cohort studies indicate that people with prediabetic conditions, such as impaired glucose tolerance, have a raised risk of future cardiovascular disease. Intervention with acarbose can prevent myocardial infarction and cardiovascular disease in type 2 diabetic and IGT patients. However, the effect of acarbose to secondary prevention of myocardial infarction or cardiovascular events in patients with newly diagnosed AGT after coronary stenting remains unclear. The purpose of the present study is to determine whether the intervention to such abnormalities after coronary stenting will improve the long-term clinical outcome. This is a opened, randomized study to compare acarbose versus a standard lifestyle modification. Patients will have a 1:1 chance of receiving acarbose versus the standard lifestyle modification. There is some research evidence that suggests acarbose may improve clinical outcome in patients with type 2 diabetes and in IGT patients.
Eligibility| Ages Eligible for Study: | 20 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Within 8 weeks since implantation of coronary artery stents for stable angina pectoris or acute coronary syndrome.
- Abnormal glucose tolerance according to a 75 g oral glucose tolerance test (OGTT).
- HbA1c is less than 6.5%.
- Age is between 20 and 75 years (at time of consent).
- Patients who can give informed consent themselves in writing.
Exclusion Criteria:
- Patients with abnormal glucose tolerance caused by other organic disorders such as pancreatitis, hemochromatosis, post pancreatectomy, hyperthyroidism, Cushing syndrome, Prader-Willi syndrome, etc.
- Patients with planned angioplasty.
- Patients with uncontrollable congestive heart failure.
- Less than 6 months since last episode of cerebral infarction.
- Patients who have received medication for diabetes mellitus before.
- AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
- Creatinine exceeding 2 mg/dl.
- Patients with a history of ileus or less than 6 months since celiotomy.
- Pregnant women or those who plan to become pregnant, or are in the lactation period.
- Habitual drinker (more than 100 ml/day of alcohol).
- Patients with a history of gastrectomy.
- Patients for whom it is impossible to follow up for 5 years.
- Any other reason that the clinical supervisors or clinical researchers may have for considering a case unsuitable for the study.
Contacts and Locations| Japan | |
| Kobe City General Hospital/Institute of Biomedical Research and Innovation | |
| Kobe, Hyogo Pref., Japan, 650-0047 | |
| Institute of Biomedical Research and Innovation. | |
| Kobe, Hyogo Pref., Japan, 650-0047 | |
| Kawasaki Medical School Hospital | |
| Kurashiki, Okayama, Japan, 701-0192 | |
| Principal Investigator: | Koichi Tamita, MD. | Division of Cardiology, Kobe General Hospital |
| Study Director: | Minako Katayama, MD | Division of Clinical Research Promotion, Institute of Biomedical Research and Innovation. |
| Study Director: | Yutaka Furukawa, MD | Division of Cardiology, Kobe General Hospital |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00221156 History of Changes |
| Other Study ID Numbers: | BRI_CAD_04-02 |
| Study First Received: | September 13, 2005 |
| Last Updated: | June 23, 2009 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare Japan: Ministry of Education, Culture, Sports, Science and Technology |
Keywords provided by Translational Research Informatics Center, Kobe, Hyogo, Japan:
|
Abnormal Glucose Tolerance coronary artery disease diabetes mellitus clinical outcome |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Metabolic Diseases Glucose Metabolism Disorders Heart Diseases Cardiovascular Diseases Arteriosclerosis |
Arterial Occlusive Diseases Vascular Diseases Acarbose Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Hypoglycemic Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013